Spironolactone-Darnitsa
Potassium-sparing diuretics. Aldosterone antagonists. Spironolactone
The active substance of the medicine, spironolactone, is a competitive aldosterone antagonist that affects the distal convoluted tubules. Due to blocking aldosterone, spironolactone suppresses water and Na+ ion retention and promotes the retention of K+ ions, which not only increases the excretion of Na+ and Cl− ions and decreases the excretion of K+ ions with urea, but also reduces the excretion of H+ ions.
– Primary hyperaldosteronism.
– Congestive heart failure — if other diuretics are ineffective or not tolerated, or if their efficacy needs to be enhanced.
– Essential hypertension, mainly with hypokalemia — usually in combination with other antihypertensive drugs.
– Hepatic cirrhosis accompanied by oedema and/or ascites.
– Oedemas caused by nephrotic syndrome.
– Hypokalemia — if other therapy is not possible.
– Prevention of hypokalemia in patients who receive cardiac glycosides — if other methods of therapy are considered inappropriate or inadvisable.
The medicine should be used orally in adults and children. The daily dose of the medicine should be taken in 1 or 2 doses after meals. The daily dose if it is taken once, or the first dose if the medicine is taken twice, is recommended in the morning.